Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor

Overview

Genzyme will evaluate/monitor the off label transplant use of plerixafor using data in the European Group for Blood and Marrow Transplantation (EBMT) registry. Off-label use of plerixafor will be collected for data entered over a 5 year time span (i.e., data entered into the registry between the date of European Union (EU) marketing authorization [31 July 2009] and 31 July 2014). The EBMT is a non-profit, scientific society representing more than 600 transplant centers mainly in Europe. The EBMT promotes all activity aiming to improve stem cell transplantation or cellular therapy, which includes registering all the activity relating to stem cell transplants. Data are entered, managed, and maintained in a central database with internet access; each EBMT center is represented in this database. The collection by the EBMT registry of reasons for the off-label transplant use of plerixafor shall provide information of a substantial number of patients who are representative of the patient population receiving plerixafor off-label.

Full Title of Study: “Monitoring of Plerixafor Off-Label Use in the European Group for Blood and Bone Marrow Transplantation (EBMT) Registry”

Study Type

  • Study Type: Observational
  • Study Design
  • Study Primary Completion Date: July 2014

Clinical Trial Outcome Measures

Primary Measures

  • Number of patients who received plerixafor outside of the label indication in Europe and the reason for administration
    • Time Frame: 5 years

Participating in This Clinical Trial

Inclusion Criteria

Patients treated with plerixafor who have 1 or more of the following:

  • Background disease other than lymphoma or multiple myeloma (MM) – Are younger than 18 years of age. – Received transplant using ex vivo plerixafor-mobilised cells (umbilical cord cell, peripheral blood (PB), bone marrow (BM) cell collection) – Received treatment with plerixafor alone (i.e., without granulocyte colony stimulating factor (G-CSF)) – Contraindication for G-CSF – Transplants using plerixafor-mobilised cells from allogeneic donor – Received transplant using plerixafor-mobilised bone marrow cells – Routes of plerixafor administration other than subcutaneous – Patients whose cells do not mobilize poorly – Other Exclusion Criteria:

  • Adults diagnosed with lymphoma or multiple myeloma (MM) and have been treated with plerixafor according to the European Union (EU) label.

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 18 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Genzyme, a Sanofi Company
  • Collaborator
    • European Society for Blood and Marrow Transplantation
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Medical Monitor, Study Director, Genzyme, a Sanofi Company

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.